Truist raised the firm’s price target on Amwell (AMWL) to $12 from $10 and keeps a Hold rating on the shares. The firm is citing improved profitability expectations relative to its prior model while also noting that shares trade at a discount to it’s historical average, which is warranted given the lack of clarity on the company’s revenue growth acceleration in the out years and breakeven profitability targets, the analyst tells investors in a research note.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- Amwell’s Earnings Call: Strategic Growth Amid Challenges
- Amwell price target raised to $10 from $9 at Stifel
- Strong Revenue Performance and Strategic Growth: Justifying the Buy Rating for American Well
- Hold Rating for American Well Amid Mixed Financial Outlook and Strategic Shifts
- Amwell Reports Improved 2024 Financial Results